| Home | E-Submission | Sitemap | Contact Us |  
J Korean Soc Ther Radiol > Volume 11(2); 1993 > Article
Journal of the Korean Society for Therapeutic Radiology 1993;11(2): 397-402.
Value of Squamous Cell Carcinoma Associated Antigen (TA-4) in Patients with Invasive Carcinoma of the Uterine Cervix
Moon June Cho, Jae Sung Kim, Seoung Ho Park, Sang Lyun Nam
1Department of Radiology, College of medicine, cancer Research Institute, Chungnam National University, Daejeon Korea.
2Department of Obstetrics and Gynecology, College of medicine, cancer Research Institute, Chungnam National University, Daejeon Korea.
We investigated the usefulness of tumor-associated antigen (TA-4) by a radioimmunoasay method in estimating the extent of disease and tracking the clinical course of disease in 58 patients with cervical cancer. According to our results and those of other authors, the normal range of serum TA-4 was arbitrarily taken to be less than 2 ng/ml. The proportion of the pretreatment positive serum TA-4 level of 48 squamous cell carcinoma patients was 60%. And 40% in 5 adenocarcinoma patients. Advanced disease group showed higher incidence of positive serum TA-4 level; 40%, 72%, 63%, and 100% in stage I to IV, respectively. And the absolute values of TA-4 were higher in advanced disease. In patients treated with radiation, elevated serum TA-4 level usually declined after 3000 cGy and further dropped to normal range in 44c13 after 5000 cGy. The Positive rate in Primary cervical cancer was 59% (32/54) and 100% (4/4) in recurrent cervical cancer. And 15 patients with recurrent or persistent disease during follow-up revealed 80% positive serum TA-4 level. In conclusion, it would be suggested that serial serum TA-4 measurements may be helpful in tracking the clinical course during and after treatment.
Key Words: TA-4, Cervix Cancer, Radiotherapy
Editorial Office
Department of Radiation Oncology, Samsung Medical Center,
Proton Therapy Center, B2, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea
Tel : +82-2-3410-3617
E-mail: rojeditor@gmail.com, roj@kosro.or.kr
Copyright © The Korean Society for Radiation Oncology.                      Developed in M2PI
Close layer
prev next